

University of Vermont
ScholarWorks @ UVM

Family Medicine Scholarly Works

College of Medicine

5-14-2013

Beta-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease

Elena Simon MD

Fletcher Allen Health Care and the University of Vermont

Follow this and additional works at: <http://scholarworks.uvm.edu/fammed>

 Part of the [Primary Care Commons](#)

Recommended Citation

Simon, Elena MD, "Beta-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease" (2013). *Family Medicine Scholarly Works*. Paper 2.
<http://scholarworks.uvm.edu/fammed/2>

This Evidence Review is brought to you for free and open access by the College of Medicine at ScholarWorks @ UVM. It has been accepted for inclusion in Family Medicine Scholarly Works by an authorized administrator of ScholarWorks @ UVM. For more information, please contact donna.omalley@uvm.edu.

FM Journal Club Bottom Line: Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease

Clinical question: Which patients should be placed/kept on beta-blocker therapy?

Bottom line answer:

- Randomized control trials show beta-blockers benefit patients with systolic congestive heart failure and for the first three years after a patient has a MI.
- Beta-blocker use may not be associated with lower event rates of CV death, non-fatal MI, stroke or hospitalization in patients even with prior history of MI after 3 years.
 - Level 2b evidence: Recent longitudinal study followed 3 cohorts of patients for 44 months with and without beta-blocker use: 1) prior MI 2) CAD no prior MI 3) risk factors for CAD only.
 - There were no significant differences in primary outcomes of cardiovascular death, non-fatal MI or non-fatal stroke in the known MI or CAD without prior MI cohorts
 - In patients with no known CAD history (only risk factors), betablocker use may be associated with increased risk of CV death, non-fatal MI and stroke (HR 1.18, p = 0.02)
 - Secondary outcomes of hospitalization for atheroembolic event and revascularization procedures were increased in patients using beta-blockers who had known CAD but no prior MI and CAD risk factors only.
 - Results were not specified for type or dose of betablocker

Case: 62 year old man who is 5 yrs s/p stent for known MI presents wanting to minimize his medications. Currently taking statin, asa, betablocker, ACEI, metformin. BP 116/72 HgA1c 6.4. Should he stop his betablocker?

Background and supporting evidence:

- AHA 2011 guidelines now recommend betablocker therapy for heart failure patients and MI or ACS patient for 3 years after MI (as class I recommendation)
- AHA guidelines recently changed its recommendation for longterm betablocker therapy from class IIa to class IIb
- European Society of Cardiology now recommends longterm betablocker therapy only for patients with left ventricular systolic dysfunction

Reference: <http://www.ncbi.nlm.nih.gov/pubmed/23032550>

Elena Simon, M.D. Family Medicine Third Year Resident